Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study
Gynecologic Oncology, Volume 141, No. 3, Year 2016
Notification
URL copied to clipboard!
Description
Objective To assess the association of hormone receptor expression with outcome in high-grade endometrial carcinomas. Methods This study included three sites participating in the Canadian High Risk Endometrial Cancer (CHREC) consortium. Sections from tissue microarrays containing cases with a diagnosis of endometrioid grade 3 (EC3) and endometrial serous carcinoma (ESC) were assessed for estrogen (ER) and progesterone receptor (PR) expression by immunohistochemistry. Expression was considered present if > 1% of tumor cell nuclei were labeled. Associations with overall survival were assessed. Results ER expression was present in 168/216 (78%) of EC3 and 124/192 (65%) of ESC. PR expression was present in 148/212 (70%) of EC3 and 83/196 (42%) of ESC. PR expression was significantly associated with favorable overall survival in EC3 and ESC (log rank, p = 0.018 and p = 0.0024) but ER expression was not. PR expression was significantly associated with favorable overall survival in EC3 independent of age, stage, center and lymph-vascular invasion (hazard ratio = 0.457, 95% CI 0.257–0.811, p = 0.0075) as well as in stage I and II ESC (hazard ratio = 0.266, 95% CI 0.094–0.750, p = 0.0123). Conclusion Our data provide support for the assessment of the PR expression status in EC3 and ESC. Future work will be required to determine how PR expression may be incorporated into management of patients with EC3 and ESC. © 2016 Elsevier Inc.
Authors & Co-Authors
Köbel, Martin
Canada, Calgary
University of Calgary
Rambau, Peter Fabian
Canada, Calgary
University of Calgary
Nelson, Gregg S.
Canada, Calgary
University of Calgary
Panzarella, Tony
Canada, Toronto
Princess Margaret Cancer Centre
Canada, Toronto
University of Toronto
Gilks, Cyril Blake
Canada, Vancouver
The University of British Columbia
Clarke, Blaise Alexander
Canada, Toronto
University of Toronto
Bernardini, Marcus Q.
Canada, Toronto
University of Toronto
Statistics
Citations: 26
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1016/j.ygyno.2016.04.008
ISSN:
00908258
Research Areas
Cancer
Environmental